BR112022000322A2 - Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer - Google Patents
Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimerInfo
- Publication number
- BR112022000322A2 BR112022000322A2 BR112022000322A BR112022000322A BR112022000322A2 BR 112022000322 A2 BR112022000322 A2 BR 112022000322A2 BR 112022000322 A BR112022000322 A BR 112022000322A BR 112022000322 A BR112022000322 A BR 112022000322A BR 112022000322 A2 BR112022000322 A2 BR 112022000322A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- alzheimer
- biomarker
- blood samples
- clinically diagnosed
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer. a presente invenção divulga um método para diagnosticar doença de alzheimer com o uso de biomarcadores, e análise multivariada que fornece um método de detecção minimamente ou não invasivo mais confiável. a invenção divulga a detecção simultânea de proteínas cd69 em linfócitos mitogênicos, proteínas tau e tau fosforiladas, e peptídeos ß-amiloides em líquido cefalorraquidiano, o que pode substituir ou suplementar os métodos convencionais de detecção de doença de alzheimer tais como testes cognitivos e tomografia por emissão de pósitrons de amiloide.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872567P | 2019-07-10 | 2019-07-10 | |
| PCT/IB2020/056509 WO2021005568A1 (en) | 2019-07-10 | 2020-07-10 | A biomarker for alzheimer's disease using blood samples from clinically diagnosed alzheimer's disease subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000322A2 true BR112022000322A2 (pt) | 2022-02-22 |
Family
ID=74114470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000322A BR112022000322A2 (pt) | 2019-07-10 | 2020-07-10 | Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220260595A1 (pt) |
| JP (1) | JP2022545153A (pt) |
| KR (1) | KR20220034769A (pt) |
| CN (1) | CN114174830A (pt) |
| BR (1) | BR112022000322A2 (pt) |
| CA (1) | CA3144876A1 (pt) |
| MX (1) | MX2022000444A (pt) |
| WO (1) | WO2021005568A1 (pt) |
| ZA (1) | ZA202201448B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
| CN115201495A (zh) * | 2022-08-29 | 2022-10-18 | 中国科学技术大学 | 诊断阿尔茨海默病的生物标志物和装置 |
| CN117210549A (zh) * | 2023-08-29 | 2023-12-12 | 河络新图生物科技(上海)有限公司 | 检测人atp5d、cd69和cxcr4基因的物质及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10349162A1 (de) * | 2003-10-22 | 2005-06-02 | Universität Leipzig | Schnelltest zur Diagnose der Alzheimerschen Erkrankung |
| US20130164217A1 (en) * | 2011-12-21 | 2013-06-27 | Meso Scale Technologies, Llc | Method of diagnosing, preventing and/or treating dementia & related disorders |
| US20130273574A1 (en) * | 2012-03-13 | 2013-10-17 | Janssen Alzheimer Immunotherapy | Oligomeric a-beta in the diagnosis, prognosis, and monitoring of alzheimer's disease |
-
2020
- 2020-07-10 CA CA3144876A patent/CA3144876A1/en active Pending
- 2020-07-10 WO PCT/IB2020/056509 patent/WO2021005568A1/en active Application Filing
- 2020-07-10 KR KR1020227000625A patent/KR20220034769A/ko unknown
- 2020-07-10 JP JP2021577534A patent/JP2022545153A/ja active Pending
- 2020-07-10 CN CN202080049419.XA patent/CN114174830A/zh active Pending
- 2020-07-10 US US17/625,344 patent/US20220260595A1/en active Pending
- 2020-07-10 MX MX2022000444A patent/MX2022000444A/es unknown
- 2020-07-10 BR BR112022000322A patent/BR112022000322A2/pt not_active Application Discontinuation
-
2022
- 2022-02-01 ZA ZA2022/01448A patent/ZA202201448B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201448B (en) | 2022-09-28 |
| CN114174830A (zh) | 2022-03-11 |
| MX2022000444A (es) | 2022-02-10 |
| JP2022545153A (ja) | 2022-10-26 |
| WO2021005568A1 (en) | 2021-01-14 |
| KR20220034769A (ko) | 2022-03-18 |
| CA3144876A1 (en) | 2021-01-14 |
| US20220260595A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lleó et al. | Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study | |
| BR112022000322A2 (pt) | Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer | |
| Toledo et al. | CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease | |
| US11307208B2 (en) | Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers | |
| Schilde et al. | Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research | |
| Lagerstedt et al. | H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury | |
| Constantinides et al. | CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes | |
| Lin et al. | Plasma biomarkers differentiate Parkinson’s disease from atypical parkinsonism syndromes | |
| Alcolea et al. | Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias | |
| German et al. | Serum biomarkers for Alzheimer's disease: proteomic discovery | |
| Devanand et al. | Intact global cognitive and olfactory ability predicts lack of transition to dementia | |
| Zhao et al. | A candidate plasma protein classifier to identify Alzheimer's disease | |
| DK3171174T3 (en) | Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease | |
| EP3088899B1 (en) | Biomarkers for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers | |
| Tavazzi et al. | A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis | |
| JP6839854B2 (ja) | 星状細胞トラウマトーム（ｔｒａｕｍａｔｏｍｅ）および神経外傷のバイオマーカー | |
| Maple-Grødem et al. | Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach | |
| Gamir-Morralla et al. | Kidins220 correlates with Tau in alzheimer’s disease brain and cerebrospinal fluid | |
| Zondra Revendova et al. | Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis | |
| JP2015524551A (ja) | アルツハイマー病及び軽度認知障害関連トロポミオシンアイソフォーム | |
| WO2015183917A2 (en) | Metabolic biomarkers for memory loss | |
| JP6947451B2 (ja) | バイオマーカー、診断用組成物、及び診断用キット | |
| JP6947448B2 (ja) | バイオマーカー、診断用組成物、及び診断用キット | |
| JP6947449B2 (ja) | バイオマーカー、診断用組成物、及び診断用キット | |
| US10502749B1 (en) | Method for patient stratification and drug efficacy monitoring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |